| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 13.8% | -8% | $13,162,175 | -$129,035 | 6,681,307 | -0.97% | RA Capital Management, L.P. | 04 Nov 2025 |
| MPM BioVentures 2014, L.P. | 8.2% | -18% | $3,619,627 | -$809,653 | 3,977,612 | -18% | ANSBERT GADICKE | 22 Dec 2025 |
| PFM Health Sciences, LP | 0.9% | -80% | $437,210 | -$2,729,747 | 401,110 | -86% | PFM Health Sciences, LP | 30 Jun 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 21,108,242 | $41,572,612 | -$2,126,394 | $1.97 | 62 |
| 2025 Q2 | 22,335,758 | $24,343,246 | -$5,335,449 | $1.09 | 65 |
| 2025 Q1 | 27,445,533 | $26,679,025 | -$940,155 | $0.9722 | 70 |
| 2024 Q4 | 28,177,146 | $41,701,476 | -$7,785,512 | $1.48 | 71 |
| 2024 Q3 | 32,205,548 | $68,274,106 | -$1,018,677 | $2.12 | 68 |
| 2024 Q2 | 32,469,409 | $79,220,415 | -$5,272,473 | $2.44 | 70 |
| 2024 Q1 | 32,251,087 | $208,968,732 | +$29,830,206 | $6.48 | 59 |
| 2023 Q4 | 27,669,999 | $106,805,060 | +$14,923,168 | $3.86 | 41 |
| 2023 Q3 | 23,882,934 | $51,107,776 | -$364,729 | $2.14 | 34 |
| 2023 Q2 | 24,045,139 | $73,334,928 | +$110,396 | $3.05 | 36 |
| 2023 Q1 | 24,035,818 | $62,491,910 | +$8,454,617 | $2.6 | 37 |
| 2022 Q4 | 20,890,957 | $42,845,289 | -$4,124,677 | $2.05 | 37 |
| 2022 Q3 | 20,956,559 | $94,490,128 | +$8,517,407 | $4.51 | 39 |
| 2022 Q2 | 19,071,418 | $78,002,023 | +$194,911 | $4.09 | 39 |
| 2022 Q1 | 18,982,797 | $83,522,100 | -$5,015,169 | $4.4 | 47 |
| 2021 Q4 | 19,103,784 | $227,525,761 | -$818,751 | $11.91 | 50 |
| 2021 Q3 | 18,418,726 | $316,117,290 | -$12,884,754 | $17.16 | 41 |
| 2021 Q2 | 19,169,179 | $334,041,360 | +$334,041,360 | $17.44 | 44 |